http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
A study of the awareness of chronic liver diseases among Korean adults
전대원,조용균,손주현,이창형,김석현,은종렬 대한간학회 2011 Clinical and Molecular Hepatology(대한간학회지) Vol.17 No.2
Background/Aims:Chronic liver disease is closely associated with lifestyle, and public enlightenment of the lifestyle factors is important in reducing prevalence of chronic liver disease. The KASL (Korean Association for the Study of the Liver) conducted a survey of basic information and epidemiological data regarding chronic liver diseases. Methods:A survey of chronic liver disease involving a total of 2,794 respondents was conducted. The respondents included patients and their guardians, visitors for health check-ups, and online pollees who completed a questionnaire on the awareness of fatty liver or chronic liver disease. Results:Of the entire cohort, 854 (39.7%) said they have had or still have fatty liver or an elevated transaminase level (>40 IU/L), but only 23.4% of the respondents had visited a hospital. It was found that 35% of healthy subjects and 45% of patients and their guardians misunderstood hepatitis B as the hereditary disesase. Furthermore, 26% of the subjects responded that patients with inactive hepatitis B do not require regular follow-up. While 17.9% answered that it is not too late to test for liver cancer when symptoms arise, 38.8% believed that liver transplant in liver cancer patients has a low success rate and is thus not recommended. Conclusions:Despite the inundation of information and widespread media advertising, the awareness of chronic liver disease is unsatisfactory among Korean adults. Systematic nationwide studies are needed to obtain data and information regarding the prevalence of chronic liver disease and patterns of use of the health-care system.
전대원 대한의사협회 2012 대한의사협회지 Vol.55 No.11
In the past 10 years, the standard treatment for chronic hepatitis C has been pegylated interferon and ribavirin for 24 to 48 weeks, based on genotype. Until now, fixed schedule therapy for chronic hepatitis C infection is the standard treatment in most countries. Response-guided therapy (RGT) is an emerging concept in which treatment decisions are based on how the virus responds to treatment. RGT has not been accepted into practice guidelines in all countries. The RGT approach takes into account both viral and host factors. RGT allows clinicians to provide a shorter duration of treatment, sparing patients of ongoing side effects and medical costs. We review several new treatment guidelines on new direct protease inhibitors. In late 2011, telaprevir and boceprevir were approved for treating chronic hepatitis C. Nowadays, the strategy for hepatitis C genotype 1 has been revolutionized by these two drugs. Other new direct acting antiviral agents have increased the sustained viral response significantly in chronic hepatitis genotype 1 patients in several recent clinical trials. In the future, Hepatitis C treatment will be personalized according to early viral response and baseline viral load. An interferon-free regimen will also be available for chronic hepatitis C.